The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INTS | -86.17% | N/A | N/A | -93% |
| S&P | +13% | +86.41% | +13.26% | +52% |
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 14.3% |
| Market Cap | $11.91M | -77.4% |
| Market Cap / Employee | $0.74M | 0.0% |
| Employees | 16 | -5.9% |
| Net Income | -$2.67M | 24.0% |
| EBITDA | -$2.73M | 23.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.07M | 154.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.09M | -25.6% |
| Short Term Debt | $0.03M | 10.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -158.62% | -11.0% |
| Return On Invested Capital | -215.42% | -93.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.39M | 39.9% |
| Operating Free Cash Flow | -$2.39M | 39.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.78 | 10.21 | 14.03 | 2.91 | -70.33% |
| Price to Tangible Book Value | 8.78 | 10.21 | 14.03 | 2.91 | -70.33% |
| Enterprise Value to EBITDA | -7.29 | -8.59 | -1.37 | -1.28 | -90.88% |
| Return on Equity | -202.3% | -298.6% | -334.1% | -234.7% | 34.90% |
| Total Debt | $0.14M | $0.13M | $0.13M | $0.12M | -18.62% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
